rustgamenft| Shanghai Pharmaceutical: I040 approved for clinical trials, and half-year sales in the antidepressant market exceed 4.5 billion yuan

News summary

Shanghai Pharmaceutical Announcement revealedrustgamenft, its innovative drug "I040" has been approved for clinical trials, specializing in the treatment of depression, and has invested 4,459 yuan in research and development expensesrustgamenft.830,000 yuan. This drug is Shanghai Pharmaceutical's first Class 1 innovative antidepressant drug, and there is no drug with the same target on the market around the world.

Newsletter text

[Shanghai pharmaceutical innovative drug "I040" was approved for clinical trials]

Shanghai Pharmaceutical recently announced that its innovative drug for depression "I040" has been approved by the State Food and Drug Administration and has officially entered the clinical trial stage.

I040 is a small molecule compound. Previous preclinical studies have shown that the drug has significant efficacy and good safety profile in multiple animal models of depression.

In August 2020, Shanghai Pharmaceutical and Shanghai Dongxi Zhihui Biomedical Co., Ltd. reached a technology development agreement to ensurerustgamenftFull intellectual property rights and commercialization rights of the drug were given. As of now, the project has invested 4,459 yuan in research and development expensesrustgamenft.830,000 yuan.

It is worth noting that no drugs with the same targets and indications have been marketed globally. In addition, Shanghai Pharmaceutical already has 6 generic antidepressant drugs on the market.

Market data shows that sales of terminal antidepressants in China's public medical institutions will exceed 8 billion yuan in 2022, and sales in the first half of 2023 will exceed 4.5 billion yuan, a year-on-year increase of 7.98%.